Pharming Group N.V.
Develops and commercializes medicines for rare, debilitating, and life-threatening diseases.
PHARM | AS
Overview
Corporate Details
- ISIN(s):
- NL0010391025 (+1 more)
- LEI:
- 724500DCJ9MPG74JEH91
- Country:
- Netherlands
- Address:
- Darwinweg 24, 2333CR Leiden
- Website:
- https://www.pharming.com/
- Sector:
- Manufacturing
Description
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2011-02-28 08:03 |
Santarus and Pharming announce receipt of FDA refusal to file letter for Rhucin…
|
English | 203.0 KB | ||
| 2011-02-22 08:11 |
Pharming and Santarus announce initiation of Phase IIIb clinical study with Rhu…
|
English | 198.1 KB | ||
| 2011-01-31 16:58 |
Pharming discontinues funding of DNage
|
English | 67.8 KB | ||
| 2010-12-28 14:45 |
Pharming and Santarus announce submission of Rhucin Biologics License Applicati…
|
English | 113.0 KB | ||
| 2010-12-28 10:12 |
Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
|
English | 108.3 KB | ||
| 2010-12-06 08:57 |
SOCIUS EXERCISES INVESTMENT RIGHTS
|
English | 69.2 KB | ||
| 2010-12-03 08:26 |
PHARMING ANNOUNCES EURO 16.1 MILLION INVESTMENT FROM SOCIUS CAPITAL GROUP
|
English | 92.5 KB | ||
| 2010-12-02 11:00 |
PHARMING AWARDED ‘BEST BIOTECHNOLOGY COMPANY’ BY THE WORLD TECHNOLOGY NETWORK
|
English | 71.0 KB | ||
| 2010-12-02 11:00 |
PHARMING AWARDED ‘BEST BIOTECHNOLOGY COMPANY’ BY THE WORLD TECHNOLOGY NETWORK
|
English | 47.0 KB | ||
| 2010-11-29 08:29 |
PHARMING ANNOUNCES TOPLINE STUDY RESULTS ON PROPHYLACTIC USE OF RUCONEST IN HER…
|
English | 74.9 KB | ||
| 2010-11-29 08:29 |
PHARMING ANNOUNCES TOPLINE STUDY RESULTS ON PROPHYLACTIC USE OF RUCONEST IN HER…
|
English | 39.0 KB | ||
| 2010-10-29 14:20 |
Pharming's Ruconest For Hae Granted European Marketing Authorization
|
English | 98.8 KB | ||
| 2010-10-21 08:44 |
Pharming announces nine month financial report 2010
|
English | 105.1 KB | ||
| 2010-10-21 07:13 | English | 105.1 KB | |||
| 2010-10-12 08:37 |
Pharming confirms anticipated call from public bondholders to exercise put opti…
|
English | 68.6 KB |
Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharming Group N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-24 | D.A. Jorn | Non-Executive member | Other | 7,446 | N/A |
| 2023-03-21 | P. Sekhri | Non-Executive member | Other | 9,363 | N/A |
| 2022-10-27 | P. Sekhri | Non-Executive member | Buy | 13,013 | 12,232.22 EUR |
| 2022-10-27 | M. Pykett | Non-Executive member | Buy | 9,760 | 9,174.40 EUR |
| 2022-08-04 | P. Sekhri | Non-Executive member | Buy | 13,013 | 10,000.23 EUR |
| 2022-08-04 | S. Baert | Non-Executive member | Buy | 9,760 | 7,500.36 EUR |
| 2022-05-25 | J. van der Meijs | Non-Executive member | Buy | 9,300 | 86,490,000.00 EUR |
| 2022-05-25 | P. Sekhri | Non-Executive member | Buy | 12,398 | 9,527.62 EUR |
| 2022-05-25 | M. Pykett | Non-Executive member | Buy | 9,300 | 7,146.86 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 318,150 | 232,249.50 EUR |
Peer Companies
